ライフサイエンスコーパス: disclosure

1 ty, justifiable risk, objectivity, warranted disclosure).

2 , graphical display, and supplemental verbal disclosure).

3 ncial ties became apparent only through self-disclosure.

4 ess of potential benefits and limitations of disclosure.

5 fferences in data availability and levels of disclosure.

6 ar of negative consequences was a barrier to disclosure.

7 Information sharing was assessed post-disclosure.

8 affective process often resulting in delayed disclosure.

9 h, although a minority strongly opposed such disclosure.

10 y and beyond, and an emphasis on openness in disclosure.

11 ptual reasons to support a policy of routine disclosure.

12 rom the intrinsic value associated with self-disclosure.

13 se of small numbers and risks of statistical disclosure.

14 proportional management of COIs beyond basic disclosure.

15 se, and are uncertain about management after disclosure.

16 e presence and making informed choices about disclosure.

17 The central theme of managing COI is disclosure.

18 iated with dietary supplement use after risk disclosure.

19 rehabilitation journals requested author COI disclosure.

20 likely to have emotional difficulties after disclosure.

21 seeking were completed before and after risk disclosure.

22 om disclosure, and baseline attitudes toward disclosure.

23 ls, athlete training management, and athlete disclosure.

24 f internal olefin are the highlights of this disclosure.

25 upport and train nurses in relation to error disclosure.

26 uidance from the organisation as barriers to disclosure.

27 errors to patients and perceived barriers to disclosure.

28 istration, and eliminating barriers to error disclosures.

29 the minimum US dollar value attributable to disclosures.

30 accuracy of physicians' conflict-of-interest disclosures.

31 ent policies for defining and soliciting COI disclosures.

32 hers are based increasingly on their digital disclosures.

33 What drives this propensity for disclosure?

34 Most articles had no disclosure (43%) or did not mention the pharmaceutical c

35 gap between prevalence of GBV (40%) and GBV disclosure (7%), implying an underestimation of GBV that

36 "extremely important" and preferred written disclosure (77%) over other methods.

37 In this disclosure, a cooperative N-heterocyclic carbene/Lewis a

38 e importance of individualised management of disclosure about a trial following a child's death.

39 ived public stigma predicted lower levels of disclosure about cancer history and experiences.

40 s and 2) situations involving a lack of full disclosure about interventions.

41 Early disclosure also reduces parental anxieties concerning di

42 hile many substances were nontoxic, frequent disclosures also included notorious groundwater contamin

43 -perfect ART adherence and mutual HIV status disclosure among all participating couples.

44 Currently, in biology, disclosure and an initial validation are combined in a j

45 aps exist between patients' expectations for disclosure and apology and physicians' ability to delive

46 rds HIV and HIV care, thus staff involved in disclosure and linkage activities should be trained to d

47 The disclosure and linkage to care experience is crucial in

48 erences and consent, variant classification, disclosure and management of primary and secondary findi

49 rs influenced Chinese MSM's decisions around disclosure and marriage.

50 and materials and activities to support HIV disclosure and parent-led health promotion.

51 Social rules of HIV disclosure and perception of risk depend on the setting

52 Hence, the disclosure and potential manipulation of such pathways m

53 In so doing, we champion disclosure and preregistration, express skepticism about

54 re, emotions involved in disclosure, desired disclosure and recommendations.

55 g and brief intervention to promote safe HIV disclosure and risk reduction in women seeking HIV couns

56 Primary outcomes were self-disclosure and social closeness.

57 cused on recognizing the association between disclosure and surgeons' well-being may help sustain ope

58 orrelation between the presence of a related disclosure and the findings of the studies (p = 0.81), a

59 on existed between the presence of a related disclosure and the results of the studies.

60 o guide 1) creation of data repositories, 2) disclosure and use of data from such repositories, and 3

61 standards for a waiver of authorization for disclosure and use of such data.

62 Individual panel members provided full disclosure and were judged to be free of any commercial

63 Individual panel members provided full disclosure and were judged to be free of any commercial

64 sent requirements, targeted consent's verbal disclosure and written form provide a way to satisfy res

65 ces are risks of research that would require disclosure and written informed consent, but data are la

66 dverse event, reported personal effects from disclosure, and baseline attitudes toward disclosure.

67 ndatory registry of locations, full chemical disclosure, and, where horizontal drilling is used, pred

68 monitoring of ART, adherence, and diagnosis disclosure are essential to optimize patient care.

69 ate youth adherence, safe sex practices, and disclosure are urgently needed.

70 Prognostic disclosures are associated with more realistic patient e

71 Main Outcomes and Measures: Self-reports of disclosure assessed by 8 items from guidelines and pilot

72 Disclosure at any level was more common in the Amagugu i

73 Surgeons with more negative attitudes about disclosure at baseline reported more anxiety about patie

74 ith 19 of these 24 journals requiring signed disclosure attestations.

75 icipants responded to a similar survey about disclosure attitudes.

76 ervention and postintervention surveys about disclosure attitudes.

77 oth physicians and patients through incident disclosure, but may be ill-prepared to disclose incident

78 Recent research has suggested interest in disclosure, but, to our knowledge, few studies have acco

79 Prognostic disclosure by skilled clinician communicators evokes a r

80 eir LE, but only 17.6% recalled a prognostic disclosure by their physician.

81 bridge the gap between existing alphabetical disclosures by function/CAS number and emerging scientif

82 Early, age appropriate disclosure can better prepare children for future consid

83 However, digital disclosures can come back to haunt, making it challengin

84 RECOMMENDATION 1 (DISCLOSURE): Clinicians should inform patients of arrhyt

85 ckground disclosure education, ensuring that disclosure coaching is available at all times, and provi

86 th commentaries less likely to have adequate disclosure compared to articles reporting original studi

87 regard to communication with families, role disclosure, consent discussions, interprofessional confl

88 emerging standard in privacy protection and disclosure control, which is known as differential priva

89 community members in the development of data disclosure (DD) strategies.

90 When faced with decisions about disclosure, decision-makers should be aware not just of

91 Disclosure decisions are also affected by cultural norms

92 A number of recent disclosures describing potent ACC inhibitors have been r

93 the paper; disclosure, emotions involved in disclosure, desired disclosure and recommendations.

94 closure support system, providing background disclosure education, ensuring that disclosure coaching

95 emes that inform the structure of the paper; disclosure, emotions involved in disclosure, desired dis

96 antitative overview relied on voluntary U.S. disclosures evaluated from the FracFocus registry by dif

97 noted logistical issues that complicated the disclosure experience.

98 We studied the effect of APOE genotype disclosure for AD risk assessment on dietary supplement

99 asizing the importance of compound structure disclosure for predicting biodegradation products.

100 te a standard potential conflict of interest disclosure form, which will be available for external re

101 te a standard potential conflict of interest disclosure form, which will be available for external re

102 e also reduces parental anxieties concerning disclosure from an unwitting source.

103 Recent disclosures from clinical trials confirm that it is well

104 The primary outcome was maternal HIV disclosure (full [using the word HIV], partial [using th

105 nd each report included one of three support disclosures: funding from a pharmaceutical company, NIH

106 In closing the "disclosure gap" an understanding of the views of all mem

107 ing about partnership separation, unintended disclosure, gender-based violence, and stigma.

108 Six-month post-disclosure, genetic risk score participants were more li

109 ime-averaged measures of anxiety (4.5 in the disclosure group and 4.4 in the nondisclosure group, P=0

110 -driven Amagugu intervention to aid parental disclosure has potential for wide-scale implementation a

111 Since 2013, a stream of disclosures has prompted reconsideration of surveillance

112 We examined the effect of genotype disclosure in a prospective, randomized, controlled tria

113 Presence of language referring to COI disclosure in the Instructions for Authors or manuscript

114 a systematic institutional approach to error disclosure in which the decision to inform the patient s

115 of the authors (22/39, 56%) made no adequate disclosures in their articles.

116 Here we break down priority into two steps: disclosure, in which the discovery is released to the wo

117 Self-disclosure increased over time for the affect dyad (slop

118 The meeting disclosure index was used to tabulate the minimum US dol

119 Cancer disclosure indirectly ameliorated psychological distress

120 Disclosure-informing advisees of a potential bias-is a p

121 Significant genotype-by-disclosure interaction effects were observed on several

122 psychological distress as mediated by cancer disclosure, internalized reactions to stigma, and social

123 influenced psychological distress via cancer disclosure, internalized shame, and social support avail

124 This increased disclosure is driven by reduced privacy concerns (study

125 or Alzheimer disease (AD) with APOE genotype disclosure is not recommended for clinical use but is av

126 sent requirements, targeted consent's verbal disclosure is preferable to waiving consent, provided a

127 Yet how likely is this, when disclosure is so harmful to the individual?

128 nses from women) used 5 of the 8 recommended disclosure items: explained why the event happened (55 o

129 , 0.0-0.52), and the Understanding Treatment Disclosure (LR+, 6.0; 95% CI, 2.1-17; LR-, 0.16; 95% CI,

130 We assessed disclosures made in articles related to the off-label us

131 determined, the value amount related to the disclosures made was inadequately reported according to

132 ts have utilized four main tools: education, disclosure, management, and prohibition.

133 IAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

134 IAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

135 IAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.

136 IAL DISCLOSURE(S): Proprietary or commercial disclosures may be found after the references.

137 ients' surgical outcomes or events following disclosure (odds ratio, 1.54; 95% CI, 1.16-2.06).

138 ion intervention predicted lower interest in disclosure (odds ratio, 2.01; 95% CI, 1.15-3.53; P = .02

139 Disclosure of a genetic risk score for CHD increased inf

140 Given the recent disclosure of a major contribution of the thymus to muri

141 The recent disclosure of a methyl-thiazole series demonstrates that

142 d to interact with them in ways that promote disclosure of actionable health information.

143 ence with AD appears to increase interest in disclosure of AD research results.

144 Interest in disclosure of AD research results.

145 o quantitatively assess surgeons' reports of disclosure of adverse events and aspects of their experi

146 Earlier disclosure of all relevant data would have better inform

147 tion in December 2014 that require mandatory disclosure of allergens in non-pre-packed foods.

148 Disclosure of amyloid imaging results is desired by many

149 Disclosure of an unconventional binding mode for 1, as r

150 rticipant introduced themselves and provided disclosure of any potential conflicts of interest.

151 The disclosure of APOE genotyping results to adult children

152 Furthermore, disclosure of APOE nonrisk may have weakened dietary res

153 Legislation mandating disclosure of breast density (BD) information has passed

154 k information led to lower LDL-C levels than disclosure of CHD risk based on conventional risk factor

155 Disclosure of CHD risk estimates that incorporated genet

156 quantify and determine the effect of author disclosure of conflict of interest on scientific reporti

157 n Agency's (EPA) current practices regarding disclosure of data underlying regulatory and policy deci

158 n Agency's (EPA) current practices regarding disclosure of data underlying regulatory and policy deci

159 ision-making conversations that include full disclosure of evidence involving surgical and nonsurgica

160 Overall, after disclosure of FFR data, management plan based on CA alon

161 Statin efficacy did not differ by disclosure of financial conflict information, use of an

162 ASCO supports thorough and accessible disclosure of financial relationships with companies at

163 ure of industry funding, as compared with no disclosure of funding, led physicians to downgrade the r

164 cle is on the prevalence and determinants of disclosure of GBV to formal authorities, including healt

165 lacking, we need to establish guidelines on disclosure of genetic information and, in the process, w

166 ty leaving nine papers which focussed on the disclosure of genetic information between parent and chi

167 al, legal, and counseling issues surrounding disclosure of genetic information generated by NGS to pa

168 Disclosure of genetic risk information about AD and CAD

169 Disclosure of genetic risk information within families i

170 ected or at risk children caused by the (non)disclosure of genetic risk information.

171 to practice and in their attitudes about the disclosure of genomic information of uncertain significa

172 mation is not sufficient, but instead a full disclosure of HF additives is necessary.

173 ent services and reducing stigma surrounding disclosure of HIV results would benefit on-going care of

174 ough a reduction in forced sex and increased disclosure of HIV results.

175 ajor factors influencing adherence were: non-disclosure of HIV status (OR = 17.99, p = 0.014); alcoho

176 that further expand HIV testing and support disclosure of HIV status are needed.

177 sits, poor PMTCT prophylaxis compliance, non-disclosure of HIV status, and non-Sukuma ethnicity.

178 Inappropriate disclosure of human genomes may put the privacy of study

179 ation, there are still good reasons to avoid disclosure of identities.

180 Disclosure of industry funding, as compared with no disc

181 ze-fits-all advice.We determined whether the disclosure of information on fat-mass and obesity-associ

182 Board of Trustees developed guidance on the disclosure of interests and management of COIs.

183 The UMHS implemented a program of full disclosure of medical errors with offers of compensation

184 In preclinical studies, these rules led to disclosure of mutation(s) in more than 10% of these fami

185 erence contrast microscopy to result in full disclosure of nanoscale motions with high accuracy.

186 ationships; a minority of journals requested disclosure of other potential conflicts such as personal

187 ed but uninfected will face the challenge of disclosure of parental HIV infection status.

188 authors review the circumstances under which disclosure of patient information about firearms to thir

189 concerns with regard to collection, use, and disclosure of patient information, this article addresse

190 sing conflicts of interest in health care is disclosure of personal financial ties to industry.

191 Disclosure of pleiotropic information did not increase a

192 Systematic disclosure of prevailing intensive care unit norms for m

193 There is increased demand for disclosure of raw data from studies used by the U.S. EPA

194 of 4 key areas pertaining to management and disclosure of risks in clinical trials: identifying and

195 Public disclosure of scientific data used by the government to

196 Findings highlight the potential benefits of disclosure of secondary genetic findings when options ex

197 Disclosure of sex and comparative studies contribute to

198 iscusses liability risks associated with the disclosure of significant research findings for investig

199 Unprotected disclosure of such information might put individual's pr

200 rly all participants described compassionate disclosure of test results by ED/UC providers, although

201 After disclosure of the 70-GS test result, the preliminary adv

202 pment of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.

203 Our disclosure of the first enantioselective synthesis of (-

204 X-ray diffractometry allowed the disclosure of the overall molecular conformation in the

205 Current guidelines generally call for simple disclosure of the presence of COI and for sponsoring pro

206 of requesting consent; and the management of disclosure of the trial after a child's death.

207 The first disclosure of the use of exo-catharanthine proceeding th

208 The disclosure of these synergic cellular mechanisms regulat

209 Forty-two percent of physicians endorsed disclosure of uncertain genomic findings to patients.

210 (or not sharing) data, combined with public disclosure of which datasets are shared and which are no

211 Moreover, earlier disclosures of an independent discovery of the quinolone

212 This paper explores the impact of disclosures of bias on advisees.

213 Intervention practices recorded 641 disclosures of domestic violence and control practices r

214 r research has focused almost exclusively on disclosures of financial conflicts of interest but littl

215 ts of interest but little is known about how disclosures of other types of biases could impact advise

216 xidizing chemicals, together with occasional disclosures of putative delayed acids and complexing age

217 emically modified apelin peptides and recent disclosures of small molecule agonists and antagonists a

218 oratory experiment, we examine and find that disclosures of specialty bias increase patients' trust a

219 The recent disclosures of two classes of acylborons, potassium acyl

220 mate their LE, those who recalled prognostic disclosure offered more realistic estimates as compared

221 ients and the impact of different aspects of disclosure on patient satisfaction.

222 ith reporting such events, and the effect of disclosure on surgeons.

223 distress 6 weeks, 6 months, and 1 year after disclosure or nondisclosure.

224 ence of industry on cancer research, greater disclosure, or both.

225 stable partner (p = 0.0008), HIV-serostatus disclosure (p = 0.009), smoking (p < 0.0001), evidence o

226 The non-disclosure patterns suggest shortcomings with authors an

227 se findings should inform the development of disclosure policies for asymptomatic individuals in AD s

228 cally evaluate the methodology, content, and disclosure policies of CPGs.

229 The disclosure policies of scientific journals now require t

230 d surgeons' well-being may help sustain open disclosure policies.

231 shared advisor-advisee decision-making, and disclosure policies.

232 esults by proposing a design for a qualified disclosure policy.

233 individuals by APOE-e4 dose for the genetic disclosure process of the Alzheimer's Prevention Initiat

234 nurses having a greater contribution to the disclosure process, but the provision of support and tra

235 Methods to simplify the disclosure process, improve transparency, and facilitate

236 ts and aspects of their experiences with the disclosure process.

237 ns about how best to structure and implement disclosure processes remain to be answered.

238 eded to determine how best to operationalize disclosure processes so as to maximize prospective benef

239 Many institutions are developing disclosure programs, and some are reporting success in c

240 To sustain open disclosure programs, it is essential to understand how s

241 riants meeting the threshold for recommended disclosure ranges from 3955-12,579 (3.79%-12.06%, 95% CI

242 Adequate disclosure rates varied significantly by article type, w

243 rom EPA's analysis of the FracFocus Chemical Disclosure Registry 1.0), 8 chemicals (22%) had an avail

244 and that the physician had misunderstood the disclosure requirements (13.9%); 11.1% reported that the

245 take a selfie (study 1) and induces greater disclosure risks (i.e., people exhibit greater disinhibi

246 c cancer disparities and have relatively low disclosure risks, which we assess by comparing individua

247 FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may

248 FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may

249 FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may

250 FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosures may

251 FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or comm

252 FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or comm

253 FINANCIAL DISCLOSURE(S): The authors have no proprietary or commer

254 FINANCIAL DISCLOSURE(S): The authors have no proprietary or commer

255 FINANCIAL DISCLOSURE(S): The authors have no proprietary or commer

256 FINANCIAL DISCLOSURE(S): The authors have no proprietary or commer

257 FINANCIAL DISCLOSURES(S): The authors have no proprietary or comme

258 epression were strongly associated with post-disclosure scores of these measures (P<0.001 for both co

259 to ascertain the possibility of bias simple disclosure seems inadequate to enable reliable assessmen

260 Learning about potential limitations of disclosure somewhat tempered interest.

261 The National Bioengineered Food Disclosure Standard requires a mandatory label for genet

262 he date of publication were used to evaluate disclosure statement accuracy, detail the companies prov

263 only 62 (15%) of which contained an adequate disclosure statement.

264 tology clinical practice guidelines, compare disclosure statements for accuracy, determine whether ph

265 estion, determined the frequency of adequate disclosure statements, and analyzed characteristics of t

266 r dermatology guidelines and the accuracy of disclosure statements.

267 testosterone in men), age, self-esteem, and disclosure status (whether LGB participants had complete

268 Narrative self-disclosure (storytelling) reduces emotional distress aft

269 Disclosure strategies alone do not provide health profes

270 risons between the nondisclosure group and a disclosure subgroup of subjects carrying the APOE epsilo

271 Such measures as hospitals establishing a disclosure support system, providing background disclosu

272 This is a much lower rate of adequate disclosure than has been identified in previous studies.

273 xperiences, were more negatively affected by disclosure than others.

274 ses identified a number of barriers to error disclosure that have already been reported in the litera

275 At an interpersonal level, disclosure to a spouse and spousal involvement in treatm

276 Non-disclosure to one's partner, as well as some cultural pr

277 e healthcare team regarding errors and their disclosure to patients is needed.

278 es, continuous self-regulation and proactive disclosure to patients.

279 of an intervention to increase maternal HIV-disclosure to primary school-aged HIV-uninfected childre

280 he advantages of separating these steps into disclosure via a preprint, and validation via a combinat

281 e (67%) of 364 radiologists responded to the disclosure vignette questions.

282 Stakeholders (n = 264) indicated that disclosure was "very important" to "extremely important"

283 The overall rate of disclosure was 71.2% (245 of 344 payments).

284 Full disclosure was also more common in the Amagugu intervent

285 In adjusted analyses, recall of prognostic disclosure was associated with a 17.2-month decrease (95

286 f evidence statements, and one commentary on disclosure was developed.

287 Interest in disclosure was high among the ADRC participants (55.1% [

288 The amount of the disclosure was incompletely reported in 30% of cases.

289 Disclosure was less common for pills than for injections

290 ers were unable to predict whether a related disclosure was made (p = 0.40).

291 ewers attempted to predict whether a related disclosure was made.

292 Prognostic disclosure was not associated with worse patient-physici

293 Only less time since disclosure was related significantly to experiencing unc

294 Self-disclosure was strongly associated with increased activa

295 he number of variants that might qualify for disclosure, we apply recently published recommendations

296 d apology and physicians' ability to deliver disclosures well.

297 hods to ensure safety and encourage violence disclosure were used.

298 , and some are reporting success in coupling disclosures with early offers of compensation to patient

299 After full implementation of a disclosure-with-offer program, the average monthly rate

300 Little is known about whether APOE genotype disclosure would actually prompt changes in nutrition be